이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Zhongzhi Pharmaceutical Holdings 관리
관리 기준 확인 3/4
Zhongzhi Pharmaceutical Holdings' CEO는 Ying Feng Lai, Mar2021 에 임명되었습니다 의 임기는 3.25 년입니다. 총 연간 보상은 CN¥ 1.39M, 79% 로 구성됩니다. 79% 급여 및 21% 보너스(회사 주식 및 옵션 포함). 는 HK$ 7.19M 가치에 해당하는 회사 주식의 0.69% 직접 소유합니다. 7.19M. 경영진과 이사회의 평균 재임 기간은 각각 3.3 년과 9 년입니다.
주요 정보
Ying Feng Lai
최고 경영자
CN¥1.4m
총 보상
| CEO 급여 비율 | 79.0% |
| CEO 임기 | 3.3yrs |
| CEO 소유권 | 0.7% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 9.1yrs |
최근 관리 업데이트
Recent updates
Calculating The Intrinsic Value Of Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)
Jun 19
Most Shareholders Will Probably Agree With Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) CEO Compensation
May 10Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
May 05Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Reducing Its Dividend To CN¥0.03
Apr 21Zhongzhi Pharmaceutical Holdings Limited's (HKG:3737) Prospects Need A Boost To Lift Shares
Feb 01These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
May 24Is Zhongzhi Pharmaceutical Holdings (HKG:3737) A Risky Investment?
Aug 26Zhongzhi Pharmaceutical Holdings (HKG:3737) Has A Pretty Healthy Balance Sheet
Apr 28These 4 Measures Indicate That Zhongzhi Pharmaceutical Holdings (HKG:3737) Is Using Debt Reasonably Well
Jun 11Investors Met With Slowing Returns on Capital At Zhongzhi Pharmaceutical Holdings (HKG:3737)
May 06Zhongzhi Pharmaceutical Holdings (HKG:3737) Strong Profits May Be Masking Some Underlying Issues
Apr 21Do Zhongzhi Pharmaceutical Holdings's (HKG:3737) Earnings Warrant Your Attention?
Mar 29The Zhongzhi Pharmaceutical Holdings (HKG:3737) Share Price Has Gained 50% And Shareholders Are Hoping For More
Mar 05Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Feb 15
What Is The Ownership Structure Like For Zhongzhi Pharmaceutical Holdings Limited (HKG:3737)?
Jan 14Would Zhongzhi Pharmaceutical Holdings Limited (HKG:3737) Be Valuable To Income Investors?
Dec 27If You Like EPS Growth Then Check Out Zhongzhi Pharmaceutical Holdings (HKG:3737) Before It's Too Late
Dec 14Did You Miss Zhongzhi Pharmaceutical Holdings' (HKG:3737) 31% Share Price Gain?
Nov 30Is Zhongzhi Pharmaceutical Holdings Limited's(HKG:3737) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 17CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2023 | CN¥1m | CN¥1m | CN¥163m |
| Sep 30 2023 | n/a | n/a | CN¥164m |
| Jun 30 2023 | n/a | n/a | CN¥164m |
| Mar 31 2023 | n/a | n/a | CN¥135m |
| Dec 31 2022 | CN¥1m | CN¥802k | CN¥106m |
| Sep 30 2022 | n/a | n/a | CN¥84m |
| Jun 30 2022 | n/a | n/a | CN¥63m |
| Mar 31 2022 | n/a | n/a | CN¥57m |
| Dec 31 2021 | CN¥1m | CN¥791k | CN¥52m |
| Sep 30 2021 | n/a | n/a | CN¥93m |
| Jun 30 2021 | n/a | n/a | CN¥133m |
| Mar 31 2021 | n/a | n/a | CN¥136m |
| Dec 31 2020 | CN¥1m | CN¥801k | CN¥139m |
| Sep 30 2020 | n/a | n/a | CN¥133m |
| Jun 30 2020 | n/a | n/a | CN¥128m |
| Mar 31 2020 | n/a | n/a | CN¥121m |
| Dec 31 2019 | CN¥986k | CN¥700k | CN¥115m |
| Sep 30 2019 | n/a | n/a | CN¥106m |
| Jun 30 2019 | n/a | n/a | CN¥97m |
| Mar 31 2019 | n/a | n/a | CN¥91m |
| Dec 31 2018 | CN¥603k | CN¥274k | CN¥85m |
보상 대 시장: Ying Feng 의 총 보상 ($USD 190.77K )은 Hong Kong 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 232.88K ).
보상과 수익: Ying Feng 의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Ying Feng Lai (32 yo)
3.3yrs
테뉴어
CN¥1,385,000
보상
Mr. Ying Feng Lai has been Executive Director of Zhongzhi Pharmaceutical Holdings Ltd since May 14, 2018 and serves as its Chief Executive since March 24, 2021. Mr. Lai joined the Group since April 2014 an...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 9.5yrs | CN¥1.92m | 60.33% CN¥ 651.3m | |
| Chief Executive & Executive Director | 3.3yrs | CN¥1.39m | 0.69% CN¥ 7.5m | |
| CFO & Executive Director | 3.3yrs | CN¥1.16m | 데이터 없음 | |
| Deputy GM & Executive Director | 3.3yrs | CN¥1.36m | 0.38% CN¥ 4.0m | |
| Company Secretary | 7.2yrs | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
42yo
평균 연령
경험이 풍부한 관리: 3737 의 관리팀은 경험 ( 3.3 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 9.5yrs | CN¥1.92m | 60.33% CN¥ 651.3m | |
| Chief Executive & Executive Director | 6.2yrs | CN¥1.39m | 0.69% CN¥ 7.5m | |
| CFO & Executive Director | 2.3yrs | CN¥1.16m | 데이터 없음 | |
| Deputy GM & Executive Director | 9.5yrs | CN¥1.36m | 0.38% CN¥ 4.0m | |
| Independent Non-Executive Director | 9.1yrs | CN¥162.00k | 데이터 없음 | |
| Non-Executive Director | 9.8yrs | CN¥270.00k | 4.89% CN¥ 52.8m | |
| Independent Non-Executive Director | 9.1yrs | CN¥162.00k | 데이터 없음 | |
| Independent Non-Executive Director | 9.1yrs | CN¥162.00k | 데이터 없음 | |
| Non-Executive Director | 2.6yrs | 데이터 없음 | 데이터 없음 |
9.1yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 이사회: 3737 의 이사회는 경험(평균 재직 기간 9 년)으로 간주됩니다.